Kiniksa reports additional mavrilimumab data

• After announcing positive Phase 2 trial data of mavrilimumab in giant cell arteritis (GCA), Kiniksa Pharmaceuticals (KNSA -1.2%) has announced updated data from the study that will be presented at the American College of Rheumatology Convergence 2020.
• Recently announced data showed the primary efficacy endpoint of time-to-first adjudicated GCA flare by Week 26 in all treated patients was statistically significant.
• In New Onset cohort showed that there was a 71% lower risk of flare in mavrilimumab recipients compared to placebo. Sustained remission rate at Week 26 was 91.3% in mavrilimumab recipients compared to 62.3% in placebo.
• In relapsing/refractory cohort, there was a 57% lower risk of flare in mavrilimumab recipients compared to placebo, and sustained remission rate at Week 26 was 72.2% in mavrilimumab recipients vs. 41.7 in placebo arm.
• https://seekingalpha.com/news/3625814-kiniksa-reports-additional-mavrilimumab-data